Stephens lowered the firm’s price target on HCA Healthcare (HCA) to $530 from $560 and keeps an Overweight rating on the shares. Q1 EBITDA came in about $60M lighter than consensus, but the company reaffirmed 2026 guidance despite the “rocky start to the year,” the analyst tells investors in a post-earnings note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare files automatic mixed securities shelf
- HCA Healthcare announces proposed public offering of senior notes
- HCA Healthcare price target lowered to $500 from $561 at TD Cowen
- HCA Healthcare price target lowered to $520 from $540 at Oppenheimer
- HCA Healthcare price target lowered to $535 from $546 at Truist